ARTICLE | Clinical News
Vivecon: Phase I data
September 22, 2008 7:00 AM UTC
In a dose-escalation Phase I trial in 55 healthy volunteers, Vivecon was well tolerated. No serious adverse events were observed. The company said Vivecon had good oral bioavailability and demonstrate...